Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study Academic Article uri icon

Overview

MeSH Major

  • Crohn Disease
  • Cytokine Receptor Common beta Subunit
  • Frameshift Mutation
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Jews

abstract

  • In both the high- and low-risk cohorts in this study, premedication use was not effective in reducing the rate of acute IFX reactions. Given this, routine premedication use is not recommended without future randomized control trials to demonstrate efficacy.

publication date

  • October 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/MIB.0000000000001189

PubMed ID

  • 28837521

Additional Document Info

start page

  • 1882

end page

  • 1889

volume

  • 23

number

  • 10